While biologics targeting tumor necrosis factor (TNF), interleukin (IL) 12/23, IL-17, and IL-23 are highly effective treatments for plaque psoriasis, they are associated with cutaneous adverse events, such as paradoxical psoriasis,
1 cutaneous lupus, and granulomatous disorders.
2 Some patients with psoriasis develop paradoxical eczema, an atopic dermatitis (AD) phenotype, during biologic exposure
3 because these dermatoses are genetically and immunologically divergent and rarely occur together
4-7; 1 meta-analysis identified a 2% prevalence of AD in those with psoriasis.
8 Furthermore, there have been reports of psoriasis or inflammatory arthritis developing secondary to IL-4/13 inhibitors used for AD.
9,10